Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIG-004
- Development stage
- Unknown
- Lead developer
- Fig Therapeutics
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
FIG-004 is a preclinical gene therapy candidate being developed by Fig Therapeutics for the treatment of solid tumors that overexpress the epidermal growth factor receptor (EGFR). The therapeutic utilizes the company's proprietary Symphony platform, which is based on a helper-dependent adenovirus (HD-Ad) viral vector system. This platform is designed to deliver targeted therapeutic payloads specifically to EGFR-positive tumor cells, aiming to enhance efficacy within the tumor microenvironment while minimizing off-target toxicity associated with systemic EGFR inhibition. As of 2024, the program is in the discovery stage.
02
Targets
Beyond the preview
Go deeper on FIG-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIG-004.